MOTS-c at a Glance

• MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame within the 12S ribosomal RNA gene (MT-RNR1) of mitochondrial DNA, rather than by the nuclear genome.
• Its best-characterised mechanism is inhibition of the folate-methionine cycle which leads to accumulation of the AMP analogue AICAR and activation of AMP-activated protein kinase (AMPK) in skeletal muscle.
• In rodents it has been reported to prevent age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the principal site of action.
• MOTS-c expression rises in human skeletal muscle after exercise and circulating levels rise transiently during and after cycling, which is the basis for describing it as an exercise-responsive mitochondrial signal.
• A naturally occurring variant, K14Q occurs at appreciable frequency in East Asian populations and has been associated in cohort studies with muscle phenotypes, sarcopenia and type 2 diabetes risk.
• MOTS-c is not an approved drug. It appears in FDA compounding materials as a withdrawn bulk-substance nomination with stated immunogenicity and characterisation concerns. All material discussed here is research-use-only.

What Is MOTS-c?

MOTS-c, mitochondrial open reading frame of the 12S rRNA type-c, is a 16-residue peptide with the sequence MRWQEMGYIFYPRKLR. It is catalogued in PubChem as CID 146675088 with the molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂ and a molecular weight of approximately 2,174 Da.

What makes it unusual is not its size but its origin. Lee and colleagues (2015, PMID 25738459) identified a short open reading frame nested within the mitochondrial 12S rRNA gene and showed that it encodes a functional peptide regulating metabolism and insulin sensitivity. Mitochondrial DNA is a circular genome of about 16.6 kilobases conventionally described as encoding thirteen polypeptides, two rRNAs and twenty-two tRNAs. MOTS-c sits outside that inventory, in a region long assumed to be purely structural RNA.

The implication is conceptual as well as pharmacological. If the mitochondrial genome encodes peptides that act outside the organelle, then mitochondria are not only the terminus of metabolic signalling but also a source of it. MOTS-c joined humanin in a class now described as mitochondrial-derived peptides, or mitochondrial microproteins.

MOTS-c is a genuine peptide in the strict sense, which distinguishes it from several compounds it sits beside in research catalogues, and it carries the handling requirements that implies.

How Does MOTS-c Work?

Folate Cycle Inhibition, AICAR and AMPK

The mechanism reported in the founding paper runs through one-carbon metabolism rather than through a membrane receptor. Lee and colleagues found that MOTS-c inhibits the folate-methionine cycle, and that the consequence of that inhibition is accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR, an intermediate of de novo purine synthesis.

AICAR is an AMP mimetic. It binds the γ subunit of AMPK at the site that normally senses AMP and activates the kinase without a change in the cell’s actual adenylate charge. The downstream consequences are the canonical AMPK programme: increased glucose uptake, increased fatty acid oxidation, suppression of anabolic biosynthesis, and transcriptional changes favouring oxidative metabolism. This is why MOTS-c is repeatedly described in the literature as acting through an AMPK-dependent axis, and why its reported effects overlap substantially with those of exercise and of metformin.

Nuclear Translocation and Retrograde Signalling

A second mechanism emerged three years later. Kim, Lee and colleagues (2018, PMC6185997) reported that under metabolic stress, glucose restriction, oxidative stress, MOTS-c translocates from the cytoplasm to the nucleus, where it associates with chromatin and regulates nuclear gene expression, including stress-response genes under antioxidant response element control.

This is retrograde signalling in the literal sense: a peptide encoded in the mitochondrial genome entering the nucleus and adjusting nuclear transcription in response to mitochondrial state. It also complicates any simple account of the compound, because two mechanisms now operate on different timescales, rapid AMPK activation and slower transcriptional reprogramming, and the relative contribution of each to any observed phenotype is not resolved.

CK2 as a Direct Binding Partner

The most recent mechanistic addition is a direct protein target. Kumagai and colleagues (2024, PMID 39559755) reported in iScience that MOTS-c binds casein kinase 2 (CK2) directly and activates it in cell-free systems. In mice, MOTS-c prevented muscle wasting and increased glucose consumption in skeletal muscle, and both effects were attenuated when CK2 activity was inhibited.

Two details from that work are particularly relevant to musculoskeletal research. The effect was tissue-directional: MOTS-c stimulated CK2 in muscle but suppressed it in adipose tissue, through distinct modifications of associated proteins. And the K14Q variant showed reduced CK2 binding and failed to produce the muscle effects, which supplies a mechanistic bridge between the biochemistry and the human cohort genetics discussed below.

Glucose Handling and Lipid Oxidation in Skeletal Muscle

Skeletal muscle is the tissue where the metabolic effects are most consistently reported, which is unsurprising given that muscle is the dominant site of insulin-stimulated glucose disposal and a major site of fatty acid oxidation. Reported muscle-level effects include increased glucose uptake, increased oxygen consumption rate in myoblasts, enhanced lipid oxidation capacity, and shifts in gene expression toward oxidative metabolism.

Work on plasma metabolites (PMC6640593) reported that MOTS-c acts as a regulator of the circulating metabolite profile and enhances insulin sensitivity, positioning it as a systemic signal rather than a purely cell-autonomous one. The broader framing of MOTS-c as a mitohormetic mediator, a signal generated by mild mitochondrial stress that produces adaptive benefit, is set out in a dedicated review of exercise, mitohormesis and the 12S rRNA open reading frame (PMID 35656563).

Research Evidence

In Vitro and Myoblast Work

Cell-level work has concentrated on C2C12 myoblasts and on primary muscle cells. In the exercise-focused work of Reynolds and colleagues (2021, published in Nature Communications), MOTS-c protected C2C12 myoblasts under combined glucose restriction and serum deprivation, producing roughly a twofold enhancement of survival at 48 hours and approximately a sixfold improvement in proliferative recovery after the stress was removed. Oxygen consumption rate rose, consistent with increased lipid oxidation capacity, and the transcriptional response implicated heat shock response and proteostasis pathways with heat shock factor 1 (HSF1) as a regulatory node.

In vitro concentrations in this literature are typically reported in the low micromolar range, and the effects are generally stress-dependent: MOTS-c tends to produce larger changes in metabolically challenged cells than in unstressed ones, which is consistent with a mitohormetic rather than a straightforwardly anabolic mode of action.

Rodent Metabolic Models

The original 2015 report established the metabolic phenotype. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity, with skeletal muscle identified as the primary target tissue. Subsequent rodent work has broadly reproduced the direction of those findings across models of insulin resistance and dietary obesity.

Doses in this literature are reported in the conventional preclinical terms, typically single-digit to mid-teens milligrams per kilogram per day, given intraperitoneally, over periods of days to weeks in mice. Reynolds and colleagues, for example, used 5 and 15 mg/kg/day by intraperitoneal injection in mice, daily for two weeks and subsequently three times weekly in the late-life arm. These figures are reported here strictly as they appear in the cited murine work; they are not dose recommendations and do not translate to any other species or route.

Skeletal Muscle, Atrophy and Exercise Capacity in Rodents

For a musculoskeletal readership this is the most directly relevant body of evidence. Kumagai and colleagues (2021, PMC8238132) reported that MOTS-c reduces myostatin and muscle atrophy signalling, which places it upstream of the canonical negative regulator of muscle mass and of the ubiquitin-proteasome atrophy programme. Later work (PMID 38170165) reported that MOTS-c attenuated immobilisation-induced skeletal muscle atrophy in a rodent model, with suppression of intramuscular lipid infiltration as a proposed contributor.

The exercise-capacity findings are the most striking in the literature. In the Reynolds work, treated young mice completed a treadmill sprint protocol at a rate of 100% at the higher dose, against 16.6% of untreated controls. In 22-month-old mice, treatment was associated with roughly a twofold increase in running duration and distance, with 17% of treated animals reaching the final speed stage against none of the untreated animals, and treated old mice outperformed untreated middle-aged animals. Grip strength and gait metrics also improved in the late-life treatment arm.

These are large effects in a narrow paradigm. Rodent treadmill performance is sensitive to motivation, handling and protocol design as well as to muscle physiology, and no equivalent controlled functional data exist in humans.

Human Exercise Physiology and Circulating MOTS-c

The human data are observational and concern endogenous MOTS-c rather than administered peptide. In the Reynolds study, skeletal muscle MOTS-c rose approximately 11.9-fold after exercise in a small cohort of young male participants, and circulating MOTS-c increased about 1.6-fold during stationary cycling and 1.5-fold afterwards, returning to baseline after four hours of rest.

Independent groups have examined the same question with broadly concordant results. Work on acute endurance exercise has reported that circulating mitochondrial-derived peptides rise with exercise in humans, a study of chronic endurance training examined serum MOTS-c and humanin in professional athletes, and further work has reported increases in skeletal muscle MOTS-c following long-term physical activity.

The cross-sectional picture in metabolic disease is less tidy than the exercise picture. A systematic review and meta-analysis of mitochondrial-derived peptides and metabolic states (PMID 39160573) found heterogeneity across studies, and more recent work reported that systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation, and remained unchanged after weight loss (PMID 41551324). Other studies have reported decreased circulating MOTS-c in obese children. Directionally inconsistent findings of this kind are common where the analyte is a small peptide measured by immunoassay, and assay validation is a live methodological issue in this field.

The K14Q Polymorphism and Cohort Genetics

A single nucleotide variant in the MOTS-c open reading frame, m.1382A>C, substitutes glutamine for lysine at position 14, giving the K14Q variant. It is essentially absent in European populations and occurs at appreciable frequency in East Asian ones, which makes it a useful natural experiment.

Fuku and colleagues (2015, PMID 26289118) raised the question of whether MOTS-c contributes to exceptional longevity, examining the variant in Japanese cohorts. Subsequent work by Zempo and colleagues (2021, PMID 34728329) reported an association between K14Q and muscle fibre composition and muscular performance, which is the most musculoskeletally specific finding in the genetic literature. The 2024 CK2 work supplied a candidate mechanism, reporting reduced CK2 binding by the K14Q peptide and loss of the muscle effects seen with wild-type MOTS-c, with elevated sarcopenia and type 2 diabetes risk in male carriers and an age-specific reduction in diabetes risk in female carriers.

The sex-specific and age-specific directionality in these findings should be read as a caution rather than a conclusion. Mitochondrial haplogroup associations are notoriously sensitive to population structure, and cohort sizes in this literature are modest.

What Remains Unknown

The gaps are substantial and worth stating directly. No interventional human trial of exogenous MOTS-c has published results; a search of the registry at ClinicalTrials.gov returns observational studies measuring MOTS-c as a biomarker rather than trials administering it. Every functional claim about administered MOTS-c rests on rodent and cell work.

The relative contribution of the three proposed mechanisms, AMPK activation via AICAR, nuclear translocation, and direct CK2 binding, has not been apportioned in any single system. Whether the peptide has a cell-surface receptor or enters cells by another route is unresolved; its uptake and intracellular trafficking are not well characterised. Pharmacokinetics in any species are thinly described, and the half-life of an unmodified 16-residue peptide in plasma is likely short, which makes the durable phenotypes reported after intermittent dosing in mice interesting rather than straightforward. Immunogenicity has not been formally assessed, and it is the specific concern the FDA recorded against the compound. Finally, whether raising MOTS-c above the range achieved by exercise adds anything over exercise itself is the question the field has not asked.

Comparison: MOTS-c, SS-31 and NAD+ Precursors

Three research approaches are frequently grouped as “mitochondrial” compounds and are mechanistically unrelated. Keeping them distinct matters for study design.

SS-31 is the nearest comparator by intent and the furthest by mechanism. Work on its mode of action (PMID 32273339) reported that it binds lipid bilayers and modulates surface electrostatics as a key component of its activity, and a body of preclinical work has examined it in renal and cardiac models. It is a structural intervention at the inner membrane; MOTS-c is a signalling intervention in the cytosol and nucleus. Laboratories running side-by-side comparisons will find SS-31 peptide and NAD+ peptide listed as separate research compounds, and the mechanistic distinctions above are the reason a study should treat them as three arms rather than three doses of the same idea.

Handling and Reconstitution of Lyophilised MOTS-c

At 16 residues and roughly 2.17 kDa, MOTS-c is a mid-sized synthetic peptide with no disulphide bonds and no post-translational modification. Handling is therefore conventional, with three sequence-specific cautions.

Its methionine residues at positions 1 and 6 and its tryptophan at position 3 are the oxidation-prone sites. Oxidation of methionine to methionine sulphoxide is the most common degradation event in peptides of this composition, promoted by dissolved oxygen, trace metals and light. Lyophilised material is comparatively robust; the reconstituted solution is where oxidation happens.

The peptide is strongly basic, carrying two arginines and a lysine, which makes it reasonably soluble in aqueous diluent without organic co-solvent, but also prone to adsorption onto glass and plastic surfaces at low concentrations. For dilute working solutions this is a real source of unexplained potency loss, and low-binding tubes are worth using.

Practical reconstitution follows the standard sequence. Allow the vial to reach room temperature before opening, so condensation does not form on the cold cake. Disinfect the septum with 70% isopropyl alcohol and let it dry. Introduce the diluent slowly down the inner wall of the vial rather than jetting it onto the cake, because a stream striking the cake generates local shear and an air-liquid interface where peptides preferentially denature. Swirl or roll gently; do not shake. Foam is a large air-liquid interface and a reliable way to aggregate a peptide before the first measurement.

Where repeated entry into the same vial is planned, most protocols specify bacteriostatic water rather than an unpreserved vehicle, on the Bacteriostatic Water for Injection, USP monograph, the diluent that suppliers such as NextGenPeps list beside the research compounds themselves. Two caveats apply. The benzyl alcohol preservative is not inert toward peptides, the formulation literature documents preservative-promoted partial unfolding and aggregation across multiple model peptides and proteins, so a single-entry analytical preparation is better served by unpreserved sterile water, which adds no destabilising excipient. And bacteriostatic water is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction that belongs in any laboratory’s handling notes even where no clinical use is contemplated.

Reconstituted solution is stored at 2–8 °C for short-term use and aliquoted into single-use portions for anything longer, protected from light. Freeze-thaw cycling is a recognised aggregation stressor, so the discipline is to aliquot at the point of reconstitution rather than to thaw one vial repeatedly. Record the resulting concentration in mg/mL rather than the volume added, and log the diluent lot alongside the peptide lot so that a stability question raised weeks later is answerable from the record.

Is MOTS-c FDA Approved?

No. MOTS-c is not approved by the FDA, the EMA or any comparable authority for any indication, in any species. There is no marketing authorisation, no approved labelling and no approved route of administration.

Its regulatory position is more specific than simple absence. The FDA’s list of certain bulk drug substances for use in compounding that may present significant safety risks records MOTS-C among nominated substances subsequently withdrawn, with the stated concern that compounded drugs containing it “may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization.” That is a documented agency position on this specific compound, not an inference from a general policy, and it is the single most useful citation available on MOTS-c’s regulatory status.

MOTS-c is also of interest to anti-doping bodies as a metabolic modulator, and laboratories working in sport science contexts should verify the current status of mitochondrial-derived peptides under the applicable prohibited list rather than assuming that absence of drug approval implies absence of prohibition.

The practical consequence is that MOTS-c sold for laboratory work is research-use-only material, and that analytical documentation from the supplier carries the whole evidentiary burden.

Where to Source Research-Grade MOTS-c

Because nothing regulatory underwrites the material, the purchase record is the only evidence a laboratory will have. What a defensible one contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory and a test date. For a 16-mer synthesised by solid-phase methods, deletion and truncation sequences are the realistic impurities, and the chromatogram should be resolved well enough to show them.
• Mass spectrometry confirming identity with an observed mass consistent with the expected 2,174 Da. Purity without identity confirmation says nothing about whether the correct sequence is in the vial.
• Declared net peptide content distinct from gross vial fill weight, since counterion and residual solvent contribute mass.
• Residual solvent and water content figures where available, because trifluoroacetate from purification and residual moisture both affect the effective mass and the storage stability.
• Cold-chain shipping and light-protective packaging appropriate to a methionine- and tryptophan-containing peptide.
• Explicit research-use-only labelling with no suggested protocol, no dosing guidance and no human-use framing anywhere in the listing.

Red flags are largely absences and overreaches. A certificate with no laboratory name, no test date or no lot reference is decoration rather than evidence, and a supplier who will not produce documentation for the lot in hand has answered the question. A listing that supplies a human protocol, an injection schedule or a performance claim has stepped outside the research-use-only frame, which is a compliance problem rather than a convenience. Purity claims of “99%+” with no chromatogram, no method and no laboratory attached are not data. Catalogues that list MOTS-C peptide as a research compound can be assessed against exactly these criteria, lot-matched third-party analysis, confirmed identity by mass spectrometry, declared net peptide content, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

What does MOTS-c stand for?

Mitochondrial open reading frame of the 12S rRNA type-c. The name describes its genomic location: a short open reading frame nested within MT-RNR1, the gene encoding the mitochondrial small-subunit ribosomal RNA.

Is MOTS-c a real endogenous peptide or a synthetic construct?

It is endogenous. Lee and colleagues identified it in 2015 as the product of a genuine short open reading frame in mitochondrial DNA, and it has since been detected in human skeletal muscle and plasma. Material used in research is synthesised to the same 16-residue sequence.

How does MOTS-c relate to exercise?

Endogenous MOTS-c is exercise-responsive. Skeletal muscle MOTS-c rose roughly twelvefold after exercise in a small human cohort, and circulating levels increased transiently during and after cycling before returning to baseline. This is the basis for describing it as a mitochondrial signal of metabolic stress, and it is why the compound is often framed as exercise-associated rather than exercise-replacing.

What is the AMPK connection?

MOTS-c inhibits the folate-methionine cycle, which causes accumulation of AICAR, an AMP analogue that activates AMPK by binding the kinase’s nucleotide-sensing site. The downstream programme, increased glucose uptake, increased fatty acid oxidation, suppressed anabolic biosynthesis, is the canonical AMPK response and accounts for much of the reported metabolic phenotype.

What is the K14Q variant?

K14Q arises from the mitochondrial variant m.1382A>C, which substitutes glutamine for lysine at position 14 of the MOTS-c peptide. It is effectively absent in European populations and present at appreciable frequency in East Asian ones. Cohort work has linked it to muscle fibre composition and muscular performance, and biochemical work has shown that the variant peptide binds CK2 less effectively and fails to reproduce the muscle effects of the wild-type sequence.

Has MOTS-c been tested in humans?

Not as an administered intervention with published results. Human data concern endogenous MOTS-c measured in muscle and plasma, and registry searches return observational studies using it as a biomarker rather than interventional trials. All functional claims about administered MOTS-c derive from rodent and cell-culture work.

What doses have been used in animal studies?

Rodent studies have typically used single-digit to mid-teens milligrams per kilogram per day by intraperitoneal injection over days to weeks; one exercise-capacity study used 5 and 15 mg/kg/day in mice. These figures are reported as they appear in the cited murine literature and do not translate to other species, routes or contexts.

How does MOTS-c compare with SS-31?

They share a stated target organelle and almost nothing else. SS-31 is a synthetic aromatic-cationic tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane and modulates membrane surface electrostatics. MOTS-c is an endogenous 16-mer encoded in mitochondrial DNA that acts through AMPK, nuclear transcription and CK2. One is a structural intervention; the other is a signalling one.

How should lyophilised MOTS-c be handled?

Bring the vial to room temperature before opening, disinfect the septum with 70% isopropyl alcohol and let it dry, add diluent slowly down the inner wall rather than onto the cake, and swirl gently rather than shaking. Store reconstituted solution cold and dark, aliquot at the point of reconstitution to avoid freeze-thaw cycling, and use low-binding tubes for dilute working solutions given the peptide’s tendency to adsorb to surfaces.

Why is MOTS-c named in FDA compounding documents if it is not approved?

Because it was nominated as a bulk drug substance for use in compounding and the nomination was withdrawn. The agency recorded a stated concern that compounded drugs containing MOTS-C may pose significant immunogenicity risk for certain routes of administration and may present complexities regarding peptide-related impurities and API characterisation. That is a specific documented position on this compound.

The Bottom Line

MOTS-c is among the more scientifically interesting compounds in the research-peptide market, and the reason is conceptual rather than pharmacological. A 16-residue peptide encoded inside a mitochondrial ribosomal RNA gene, activating AMPK through a one-carbon metabolism intermediate, entering the nucleus to adjust transcription, and binding a protein kinase directly, that is a genuinely novel signalling architecture, and it was not predicted by the mitochondrial genome’s conventional annotation.

The preclinical record in skeletal muscle is coherent and points consistently in one direction: improved insulin sensitivity, reduced atrophy signalling through myostatin, protection against immobilisation-induced atrophy, increased oxidative capacity in myoblasts, and large improvements in rodent exercise capacity including in old animals. For a musculoskeletal research programme, that is a well-motivated compound with a clear mechanistic hypothesis and clear endpoints.

The human record is thin and observational. Endogenous MOTS-c responds to exercise in human muscle and plasma, and a naturally occurring variant tracks with muscle phenotypes in East Asian cohorts. Beyond that, nothing: no published interventional trial, no pharmacokinetics worth the name, no immunogenicity assessment, and no evidence that supplying exogenous peptide adds anything over the exercise that induces it endogenously.

That asymmetry defines the honest position. MOTS-c is a strong research target and an unapproved, immunogenicity-flagged compound. Laboratories that keep both statements in view, rigorous about the mechanism, rigorous about the sourcing, and unwilling to import rodent effect sizes into human expectations, are the ones producing work worth citing.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

MOTS-c and all other compounds discussed in this article are intended for laboratory research use only. MOTS-c is not approved by the U.S. Food and Drug Administration or any comparable regulatory authority for the diagnosis, treatment, cure or prevention of any disease, and it appears in FDA compounding materials as a withdrawn bulk-substance nomination with stated immunogenicity and characterisation concerns. Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it should be interpreted as a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind.

Research peptides described here are not for human or veterinary use. Doses and concentrations quoted from the published literature are reported in the terms the original investigators used, milligrams per kilogram in the named animal model, or molar concentrations in the named cell system, and are not recommendations, conversions or equivalents for any other species or route. Readers with clinical questions should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Related posts:

How Advanced Nursing Roles Are Improving Patient Care Outcomes 6 Best Remineralizing Toothpaste For Enamel Repair: Picks for Sensitive Teeth, Receding Gums, and Early Erosion How Healthcare Is Evolving to Meet Modern Patient Needs How Motion-Tracking Gadgets Improve Physical Therapy Accuracy Buy BPC-157 Peptide: Dosage, Side Effects, and How To Get BPC-157 Products in 2026 Best Peptides for Muscle Growth: A Research-Based Look at the Top Options

Stay updated, free articles. Join our Telegram channel

Join